8-KEarnings & ResultsLeadership ChangesRegulation FD+1

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Oct 28, 2021)

Filed October 28, 2021For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced its third-quarter 2021 financial results, alongside a significant leadership transition. While the financial details themselves are not detailed in this 8-K, the filing notes the release of this information. The key strategic development is the planned CEO transition, with Dr. Yvonne L. Greenstreet set to assume the CEO role from Dr. John M. Maraganore, effective January 1, 2022. Dr. Maraganore, who has led the company for nearly two decades, will transition to a role on the Scientific Advisory Board and will provide consulting services. This leadership change positions Dr. Greenstreet, currently President and COO with extensive experience in the pharmaceutical industry including roles at Pfizer and GSK, to guide Alnylam's future growth and development. The company also announced an expansion of the Board of Directors to accommodate Dr. Greenstreet's new role. Investors should look to the accompanying press releases for detailed financial performance and further strategic insights related to this leadership evolution.

Key Highlights

  • 1Effective January 1, 2022, Yvonne L. Greenstreet will become the new Chief Executive Officer, succeeding John M. Maraganore.
  • 2Dr. John M. Maraganore will depart as CEO on December 31, 2021, after nearly 19 years with the company.
  • 3Dr. Maraganore will remain involved as a member of Alnylam's Scientific Advisory Board.
  • 4Yvonne L. Greenstreet's appointment as CEO follows her tenure as President and Chief Operating Officer.
  • 5Dr. Greenstreet has been appointed to the Board of Directors, effective October 28, 2021.
  • 6Dr. Maraganore will provide consulting services to the company for three months post-departure.
  • 7Dr. Maraganore's departure will be treated as a resignation for 'Good Reason' or termination without 'Cause', impacting equity awards and options as per his employment agreement.

Frequently Asked Questions

This 8-K filing announces that Alnylam released its Q3 2021 financial results on October 28, 2021. However, the specific financial details (revenue, net income, etc.) are not included in the 8-K itself but are available in the furnished press release (Exhibit 99.1).

Yvonne L. Greenstreet, currently the President and Chief Operating Officer, has been appointed as the new Chief Executive Officer, effective January 1, 2022. Dr. Maraganore will step down as CEO on December 31, 2021.

Yes, Dr. Maraganore will continue to support the company as a member of its Scientific Advisory Board. He will also provide consulting services for a period of three months following his departure.

Dr. Greenstreet has extensive experience in the pharmaceutical industry. Prior to her current role as President and COO, she held senior leadership positions at Pfizer Inc. and GlaxoSmithKline plc (GSK), where she spent 18 years. She also founded Highgate LLC and serves on the Scientific Advisory Committee of the Bill and Melinda Gates Foundation and on the boards of several other companies.